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Immunoepidemiological studies typically reveal slow, age-dependent acquisition of 
immune responses against Plasmodium falciparum sporozoites. Naturally acquired immu- 
nity against preerythrocytic stages is considered inadequate to confer protection against 
clinical malaria. To explore previously unrecognized antisporozoite responses, we mea-
sured serum levels of naturally acquired antibodies to whole Plasmodium falciparum 
sporozoites (Pfspz) and the immunodominant (NANP)5 repeats of the major sporozoite 
surface protein, circumsporozoite protein, in a well-characterized Kenyan cohort. Sera 
were sampled at the start of the malaria transmission season, and all subjects were 
prospectively monitored for uncomplicated clinical malaria in the ensuing 6 months. We 
used Kaplan–Meier analysis and multivariable regression to investigate the association 
of antisporozoite immunity with incidence of clinical malaria. Although naturally acquired 
humoral responses against Pfspz and (NANP)5 were strongly correlated (p < 0.0001), 
37% of Pfspz responders did not recognize (NANP)5. The prevalence and magnitude 
of antisporozoite responses increased with age, although some high Pfspz responders 
were identified among children. Survival analysis revealed a reduced risk of and increased 
time to first or only episode of clinical malaria among Pfspz or (NANP)5 responders car-
rying microscopically detectable Plasmodium falciparum (Pf) parasitemia at the start of 
the transmission season (p < 0.03). Our Cox regression interaction models indicated a 
potentially protective interaction between high anti-Pfspz (p =  0.002) or anti-(NANP)5 
(p = 0.001) antibody levels and microscopically detectable Pf parasitemia on the risk 
of subsequent clinical malaria. Our findings indicate that robust antisporozoite immune 
responses can be naturally acquired already at an early age. A potentially protective 
Abbreviations: Pf, Plasmodium falciparum; Pfspz, whole Plasmodium falciparum sporozoites; CSP, circumsporozoite protein 
(major sporozoite surface protein); (NANP)5, immunodominant icosapeptide repeats of Pf circumsporozoite protein; CRR, 
central repeat region of circumsporozoite protein; MSP1-3, merozoite surface proteins 1-3; AMA1, apical membrane antigen-1; 
EBA-175, erythrocyte binding antigen 175.
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role of high levels of anti-Pfspz antibodies against clinical episodes of uncomplicated 
malaria was detected, suggesting that antibody-mediated preerythrocytic immunity 
might indeed contribute to protection in nature.
Keywords: malaria, Plasmodium falciparum, sporozoites, humoral immunity, clinical malaria, protective immunity
inTrODUcTiOn
Malaria transmission by Plasmodium-infected Anopheles mos-
quitoes results in at least 200 million malaria cases every year, 
and the majority of disease burden is caused by Plasmodium 
falciparum (Pf) infections in children (1).
During a blood meal, an infected mosquito typically injects 
fewer than 40 motile sporozoites into the human skin (2). After 
injection, a proportion of sporozoites reaches a blood capillary 
by active intradermal migration, breaches the endothelial cells of 
the blood vessel, and is passively transported to the liver through 
the blood circulation. Following a massive replication phase in 
hepatocytes, tens of thousands of liver merozoites are released 
to initiate asexual parasite propagation in erythrocytes, the only 
phase in the parasite life cycle causing malaria symptoms.
When experimentally inoculated in repeated high doses, 
arrested, but metabolically active, Plasmodium sporozoites are able 
to elicit protective and often lasting and sterile immune responses 
against homologous challenge in humans (3–5). Because the 
preerythrocytic phase of the life cycle is clinically silent, humans 
can be inoculated with high doses of sporozoites, providing a tan-
talizing rationale for preerythrocytic malaria vaccine approaches 
(6). Plasmodium sporozoites are considered immunologically 
silent in natural infections, because they are mostly inoculated in 
small numbers and are exposed to the immune system only for 
a brief period (7, 8).
Naturally acquired immune responses against whole Pf sporo-
zoites (Pfspz) typically reveal age- and transmission-dependent 
increases in prevalence (9–11). Strong humoral responses are 
directed against the central repeat region (CRR) of the major 
sporozoite surface protein, circumsporozoite protein (CSP) 
(12–17). The CRR is composed of a varying number of NANP 
repeats, and a single Pf sporozoite inoculation is sufficient to trig-
ger anti-NANP antibody responses (15, 18). However, in virtually 
all populations studied, a varying proportion of naturally exposed 
individuals remains unresponsive to NANP repeats, even after 
repeated exposures (19).
In addition to NANP repeats, immune responses can also tar-
get regions in the amino- or carboxy-termini of CSP  (20–22) or 
additional sporozoite antigens, such as thrombospondin-related 
anonymous protein (23–25) or sporozoite threonine–asparagine-
rich protein (26, 27). However, no single preerythrocytic antigen 
has yet been identified that serves as a correlate of naturally 
acquired protection against infection or clinical disease. Rather, 
immunoepidemiological studies show that the breadth of 
preerythrocytic antigens recognized by an individual is associated 
with a lower risk of and an extended time to reinfection (28, 29).
In this study, we analyzed humoral immune responses against 
Pfspz in a cohort of naturally exposed individuals in Kenya. 
We compared prevalence and titers of antibodies against whole 
Pfspz and NANP repeats of CSP and assessed potentially protective 
contributions of antisporozoite immunity against clinical malaria. 
We show previously unrecognized high anti-Pfspz responses 
in children, which are not captured by (NANP)5-enzyme-linked 
immunosorbent assay (ELISA), and demonstrate potentially pro-
tective interactions between high levels of anti-Pfspz respon ses 
and asymptomatic Pf slide positivity at the time of serum collection 
on the risk of clinical malaria.
MaTerials anD MeThODs
study Design and cohort
This was a follow-up study from seroepidemiological cohort 
studies previously conducted in Chonyi village (Kilifi County, 
Kenya) (30–34). At the time the study was conducted, this 
region experienced year-round moderate malaria transmission 
(~20–100 infective bites/person/year), with a short rainy season 
from November to December and an extended one from June 
to August causing two seasonal peaks in transmission (35). 
Details of the cohort and study area have been published previ-
ously (36). For this study, serum samples of 514 individuals aged 
1.6 months–82 years were analyzed from the cross-sectional bleed 
conducted in October 2000, immediately prior to the start of the 
malaria transmission season. At the time of this cross-sectional 
bleed, no individual experienced clinical malaria episodes, 
but 37% carried a microscopically detectable asymptomatic 
Pf blood stage infection, as assessed by thick and thin blood 
films. Asymptomatic infection was defined as any micro-
scopically detectable parasitemia in an afebrile individual. We 
measured serum levels of antibodies to (i) whole Pfspz and 
(ii) the (NANP)5 repeats of CSP. Active weekly surveillance and 
passive case detection for development of clinical malaria during 
a 26-week follow-up permitted a retrospective analysis of poten-
tial associations of humoral antisporozoite immune responses 
with incidence of clinical malaria, which was defined according to 
the following age-specific criteria: for infants <1-year old and for 
older children and adults (≥15 years old), an axillary temperature 
of ≥37.5°C plus any parasitemia; for children aged 1–14 years, 
an axillary temperature of ≥37.5°C, combined with a parasitemia 
of ≥2,500 parasites/μl (36).
generation of Pf sporozoites
Plasmodium falciparum gametocyte cultures were derived 
from high parasitemic (5–8%) asexual PfNF54 parasites, cul-
tured in pooled human O+ red blood cells and RPMI-HEPES 
medium, supplemented with hypoxanthine, sodium carbonate, 
l-glutamine, and pooled, non-immune, heat-inactivated human 
A+ serum. The asexual Pf culture was diluted to 1% parasitemia 
into culture flasks containing 6 ml prewarmed medium, resulting 
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in a final hematocrit of 5%, and gas flushed with 5% O2 and 5% 
CO2. Medium was replaced daily. From day 14 onward, cultures 
were examined daily for stage V gametocytemia, male:female 
ratio, and exflagellation rates. Infection of Anopheles stephensi 
mosquitoes was done by membrane feeding for 15 min at 26°C in 
the dark. Mosquitoes were maintained at 26°C and 80% humid-
ity. Salivary glands were liberated between days 18 and 20 after 
infection by hand dissection in RPMI/3% BSA. Salivary glands 
were gently ground in a test tube, and the sporozoite suspension 
was centrifuged at 20 × g for 3 min to remove mosquito tissue 
debris. The mean sporozoite number per mosquito was 7,400. 
Two thousand to four thousand sporozoites per well were added 
to eight-well chamber slides (Medco), air dried, and stored at 
room temperature.
Detection of anti-Pfspz antibodies  
by immunofluorescence assay (iFa)
For fixation, sporozoite slides were dipped in cold acetone for 
1 min and rehydrated in PBS for 30 min. All incubation steps were 
done in a dark humid chamber for 1 h at 37°C. Blocking was done 
with PBS/3% BSA. After washing with PBS/0.5% BSA, human 
sera were added in serial dilutions ranging from 1:50 to 1:24,300 
in PBS/0.5% BSA, followed by extensive washing with PBS/0.5% 
BSA. AlexaFluor488 goat anti-human IgG (1:500; Invitrogen) and 
Hoechst (1:1,000; Invitrogen) were used as secondary fluorescent 
antibody and nuclear stain, respectively. Slides were sealed after 
addition of Fluoromount (Southern Biotech) and analyzed by 
fluorescence microscopy. For the negative control, one well per 
slide was stained with pooled sera from 20 unexposed individu-
als from the United Kingdom. The pooled negative control sera 
did not deliver any IFA signal detectable by visual examination 
even at the lowest dilution. Cohort sera displaying a comparable 
response were considered to be IFA negative or unresponsive 
to Pfspz. For the positive control, one well per slide was stained 
with an anti-PfCSP antibody (2A10) (37) or a Kenyan adult 
hyper immune serum. All IFA slides were randomized prior to 
microscopic screening to avoid biased evaluation, and arbitrary 
sample batches were repeated to exclude day-to-day variation of 
the assay. The reciprocal antisporozoite end titer was defined as 
the last dilution at which immunofluorescence was detectable by 
fluorescence microscopy.
Detection of serum antibodies by elisa
To quantify serum antibody titers against the CRR of CSP, a 
standard ELISA was performed using the (NANP)5-icosapeptide 
(Peptides and Elephants, Potsdam, Germany). A peptide stock 
solution (1  µg/µl) was prepared in sodium carbonate buffer 
(pH 9.3) and stored at −80°C. For experiments, the stock solution 
was diluted to a concentration of 400 ng/100 μl. F96 MaxiSorp 
plates (Nunc) were coated with peptide overnight at 4°C 
(400  ng/well). After extensive washing with PBS/0.05% Tween, 
unspecific binding was blocked with 100  µl casein (Thermo 
Scientific Blocker). After an additional wash, human sera (1:200 
in 100 µl casein) were incubated for 1 h at 37°C. After extensive 
washing, plates were incubated for 1 h at 37°C with horseradish 
peroxidase-conjugated rabbit anti-human IgG (Dako Ltd.) at 
a 1:3,000 dilution in 100  µl casein. Following washing, bound 
human IgG was measured with OPD substrate (Sigmafast). The 
reactions were stopped with 50 µl 2 M H2SO4, and absorbance was 
read in an ELISA plate reader at 492 nm. To assess the variability 
of the ELISA assay, all sera were tested in duplicates, and the coef-
ficient of variation was calculated for each paired serum sample. 
Samples that varied by ≥20% were tested again. A hyper immune 
Kenyan adult serum was used in duplicates on each ELISA plate 
as a positive control. The ratio of mean optical densities (ODs) 
of the positive serum samples was computed to assess plate to 
plate and day-to-day variability. For ratios ranging between 1.1 
and 1.3 or 0.7 and 0.89, OD values were multiplied to adjust the 
data to a reference plate. For ratios <0.7 or >1.3, the experiment 
was repeated. Twenty sera from unexposed individuals from 
the United Kingdom were used as negative controls. The mean 
OD plus three SDs from all negative controls was determined as 
a cutoff for (NANP)5 seropositivity. ELISAs to measure serum 
levels of antibodies against Pf schizont extract and blood stage 
merozoite antigens were described previously (31).
statistical analysis
A Spearman’s correlation was run to assess the relationship 
between ELISA ODs and IFA end titers. The Kruskal–Wallis test 
was applied for non-parametric analyses of variance in levels of 
antisporozoite antibodies across age groups. The Pearson’s χ2 test 
was used to determine the statistical significance of differences 
between proportions. The Mann–Whitney test determined statis-
tically significant differences in antibody titer between two subsets 
of individuals. A binomial general linear model was used to 
calculate risk ratios in univariate analysis. Kaplan–Meier survival 
analysis and the log-rank Mantel–Cox test were used to compare 
the incidence of clinical malaria in distinct subsets of the cohort.
For multivariable analyses, we used a fractional polynomial 
Cox regression model that best predicts the time to first or only 
episode of clinical malaria for individuals with different levels of 
antisporozoite antibodies and predicted the log relative hazard 
against increasing levels of antibodies. Stepwise regression was 
conducted to select the most parsimonious set of covariates that 
are best predictors of clinical malaria. The variables with least 
significant coefficients (p > 0.2) were dropped one at a time until 
the final model was obtained. Likelihood ratio tests were run to 
compare the fit of the models with and without each variable. 
The final model was adjusted for the following confounders: 
age, plasma levels of antibodies against blood stage antigens 
[merozoite surface proteins 1-3 (MSP1-3), apical membrane 
antigen-1 (AMA1), erythrocyte binding antigen 175 (EBA-175), 
and Pf schizont extract], and malaria exposure, or unweighted 
local malaria prevalence index, as measured by the proportion of 
infected individuals within a 1 km radius of the index case. The 
malaria exposure index was calculated over the 6-month follow-
up period using weekly slide data for acute episodes only (active 
case detection) and using the cross-sectional slide data (38).
To examine the effect of interactions between baseline 
antisporozoite antibody levels and microscopically detectable 
Pf parasitemia on malaria risk, hazard ratios were computed 
through a Cox regression model with and without one-, two-, or 
three-way interactions between antisporozoite antibody levels, 
FigUre 1 | naturally acquired antibody responses against 
Plasmodium falciparum (Pf) sporozoites. Antibody responses to whole 
Pf sporozoites (Pfspz) and to the central repeat region of the 
circumsporozoite protein were measured by immunofluorescence assay 
(IFA)  on air-dried Pfspz and enzyme-linked immunosorbent assay (ELISA) 
using (NANP)5 peptide, respectively. Anti-Pfspz end titers were defined as the 
last dilution at which sera recognized Pfspz by IFA. Anti-Pfspz antibody titers 
are log transformed. The (NANP)5-ELISA seropositivity cutoff (dashed line) 
was defined as the mean optical density (OD) plus 3 SDs of 20 sera from 
unexposed individuals (OD = 0.135). Serum from a hyperimmune Kenyan 
adult (20H) served as a positive control; black line: fitted regression line; 
Spearman’s ρ = 0.668; p < 0.0001.
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microscopically detectable Pf infection, and malaria exposure 
index. Models with and without interactions were compared 
using the log likelihood ratio test.
The fractional polynomial Cox regression model and the 
interaction model are presented using anti-(NANP)5 ODs as a 
continuous variable. To reduce the skewness while maintaining 
the direction of association, anti-(NANP)5 OD values were trans-
formed to negative inverse values before running the models.
Data were compared for statistically significant differences 
at a significance level of α =  0.05. The Bonferroni correction 
was applied to control for the increasing familywise error rate 
through multiple comparisons. Four families of statistical tests 
were defined based on the common dependent variable and null 
hypothesis tested. For each family composed of k significance 
tests, a new critical value was defined as α/k. Individual tests 
within these families were considered significant at α = 0.05 level 
if p < (α/k). The following families were defined:
 1. Association of anti-Pfspz or anti-(NANP)5 antibody preva-
lence or titers with age; k = 8; αnew = 0.05/8 = 0.006.
 2. Association of anti-Pfspz or anti-(NANP)5 antibody prevalence 
or titers with blood film status (for each separate age category), 
k = (4 tests × 9 age categories) = 36; αnew = 0.05/36 = 0.001.
 3. Association of anti-Pfspz or anti-(NANP)5 antibody levels 
with incidence of clinical malaria; k = 4; αnew = 0.05/4 = 0.013.
 4. Interaction of anti-Pfspz or anti-(NANP)5 antibody levels with 
blood film positivity status and association with incidence 
of clinical malaria; k = 14; αnew = 0.05/14 = 0.004.
All statistical analyses were performed using STATA/SE12 
(StataCorp).
resUlTs
incidence of clinical Malaria
Overall, the risk of developing at least one episode of clini-
cal malaria during 6  months of follow-up decreased with age 
(p <  0.0001), with an overall rate of 0.4 episodes/person/year 
(Table S1 in Supplementary Material).
Asymptomatic Pf blood stage infection at the beginning of the 
malaria transmission season was detected in 37% of individu-
als, although this proportion was higher in younger age groups 
(3–15 years) (Table S1 in Supplementary Material). One or more 
malaria episodes were reported in 22% of blood film-positive 
individuals (Table S1 in Supplementary Material). This propor-
tion was significantly lower (11%) among subjects who were 
blood film negative at the beginning of the observation period 
(p =  0.001) (Table S1 in Supplementary Material). This group 
may include parasite-free individuals and subjects carrying Pf 
parasites below the detection threshold by microscopy.
naturally acquired antibody responses 
against Pf sporozoites
A substantial fraction (63%) of the Chonyi sera recognized 
air-dried, whole Pfspz by IFA (Figure  1). The proportion of 
anti-(NANP)5 responders was substantially lower (27%), and all 
(NANP)5-reac tive individuals except three were also classified as 
Pfspz responders (Figure 1). A large subset (36%) of sera recog-
nized Pfspz but not (NANP)5. We observed an overall correlation 
of increased intensity of (NANP)5 responses in individuals with 
high anti-Pfspz titers (p <  0.0001) (Figure  1). However, even 
among the sera that produced the highest Pfspz reactivities by 
IFA, some remained (NANP)5 negative (Figure 1).
Stratification of the Chonyi cohort revealed age-dependent 
acquisition of anti-Pfspz antibodies (p < 0.0001). The age-related 
increase in prevalence was particularly accentuated among blood 
film-negative individuals (p <  0.001) (Figure  2A). This was in 
marked contrast with blood film-positive individuals (p = 0.72), 
where prevalence of anti-Pfspz responses reached 68% in children 
younger than 6 years (Figure 2A). In individual age groups, the 
proportion of Pfspz responders was consistently higher among 
blood film-positive individuals, although this difference was 
only significant among individuals aged 7–8  years (p =  0.001) 
(Figure 2A).
Despite the presence of several high responders among 
children, anti-Pfspz antibody titers significantly correlated with 
age (p < 0.001) (Figure 2B). This was significant among blood 
film-negative individuals (p = 0.001), but not blood film-positive 
individuals (p = 0.08). Differences in median end titer between 
the two cohort subsets were non-significant in all age groups.
Acquisition of antibodies against the PfCSP repetitive region 
(NANP)5 occurred in an age-dependent manner (p <  0.0001). 
Anti-(NANP)5 antibody acquisition correlated with age among 
blood film-negative individuals (p < 0.001) and blood film-positive 
individuals (p = 0.002) (Figure 2C). The proportion of (NANP)5-
reactive sera was comparable between blood film-positive indi-
viduals and blood film-negative individuals.
FigUre 2 | age-dependent acquisition of antisporozoite antibodies and correlation with microscopically detectable Plasmodium falciparum 
(Pf)  infection. (a) Proportion of sera responding to Pf spzorozoites (Pfspz) by immunofluorescence assay (IFA) in each age group, stratified by blood film positivity. 
Anti-Pfspz antibody prevalence was significantly correlated with age among blood film-negative individuals (Pearson’s χ2 = 73.2; p < 0.001), but not blood 
film-positive individuals (Pearson’s χ2 = 5.4; p = 0.719). In all age groups, the proportion of responders was higher among blood film-positive individuals, but this 
was only significant among young individuals aged 7–8 years (Pearson’s χ2 = 10.8; p = 0.001). (B) Distribution of anti-Pfspz antibody titers by age category, 
excluding IFA-non-responders. Anti-Pfspz antibody titers are plotted on a log scale. Median anti-Pfspz antibody titers increased significantly with increasing age 
(Kruskal–Wallis test: χ2 = 32.7; p < 0.001). Each serum was tested in threefold serial dilutions (1:50–1:24,300). The number of high responders was detected in all 
age groups. Within individual age groups, differences in antibody levels between blood film-positive individuals and blood film-negative individuals were non-
significant (Mann–Whitney test: p > 0.05). Boxes and horizontal bars indicate the 75th and 25th percentiles and median, respectively. Circles and triangles represent 
individual sera of blood film-negative or blood film-positive individuals, respectively. Whiskers represent minimum and maximum values. (c) Proportion of sera 
responding to (NANP)5 by enzyme-linked immunosorbent assay (ELISA) in each age group, stratified by blood film positivity. The proportion of (NANP)5-seropositive 
sera increased with age in both blood film-negative subjects (Pearson’s χ2 = 95.9; p < 0.001) and blood film-positive individuals (Pearson’s χ2 = 23.9; p = 0.002). 
Within each age group, the proportion of responders was similar in blood film-positive individuals and blood film-negative individuals. (D) Distribution of anti-(NANP)5 
antibody titers by age category. There was an age-dependent increase in median anti-(NANP)5 titers, but this was not statistically significant (Kruskal–Wallis test: 
χ2 = 11.2; p = 0.193). Differences in anti-(NANP)5 antibody levels among blood film-positive individuals or blood film-negative individuals were non-significant in all 
age groups (Mann–Whitney test: p < 0.05); dashed line: ELISA seropositivity cutoff = 0.135. Boxes and horizontal bars indicate the 75th and 25th percentiles and 
median, respectively. Circles and triangles represent individual sera of blood film-negative or blood film-positive individuals, respectively. Whiskers represent minimum 
and maximum values.
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There was an age-dependent increase in levels of anti-(NANP)5 
antibodies, but this increase was not statistically significant 
(p = 0.19) (Figure 2D). Levels of anti-(NANP)5 antibodies were 
comparable between blood film-negative and blood film-positive 
individuals.
correlation of antibodies against Pf 
sporozoites with Malaria incidence
Univariate Analysis
In univariate analysis, there was no marked difference in the 
cumulative risk of clinical malaria depending on Pfspz responder 
status (p = 0.19) (Table S2 in Supplementary Material). However, 
the risk of clinical malaria was significantly reduced among Pfspz 
responders who were blood film positive at the beginning of 
follow-up (p = 0.015). This association was not observed among 
blood film-negative individuals.
Overall, individuals with a positive antibody response to 
(NANP)5 displayed a significantly lower risk of clinical malaria 
during follow-up (p = 0.006), although this association was only 
significant among blood film-positive individuals (p  =  0.03) 
(Table S2 in Supplementary Material).
Survival Analysis
According to Kaplan–Meier analysis, antibodies against whole 
Pfspz did not have any impact on clinical malaria incidence 
FigUre 3 | Kaplan–Meier analysis of time to clinical malaria during the 26-week follow-up. Survival curves display the proportion of malaria-free individuals 
over time, stratified by anti-Pfspz antibody titer (a,B) or (NANP)5-seropositivity status (c,D). (a) Among blood film-negative individuals, serum levels of anti-Pfspz 
antibodies did not have an impact on the incidence of clinical malaria (log-rank Mantel–Cox test: χ2 = 0.81; p = 0.847). (B) High anti-Pfspz antibody titers were 
significantly associated with a reduced risk of and increased time to first clinical episode among blood film-positive individuals (log-rank Mantel–Cox test: χ2 = 10.65; 
p = 0.014). (c) Anti-(NANP)5 seropositivity did not correlate with malaria incidence among blood film-negative individuals (log-rank Mantel–Cox test: χ2 = 2.74; 
p = 0.098). (D) Anti-(NANP)5 seropositivity was significantly associated with reduced malaria incidence among blood film-positive individuals (log-rank Mantel–Cox 
test: χ2 = 5.02; p = 0.025).
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among individuals who were blood film negative at the time of 
serum collection (p = 0.85) (Figure 3A). In marked contrast, low 
(1:50–1:100), moderate (1:300–1:2,700), and high (≥1:8,100) 
anti-Pfspz titers correlated with a reduced risk of and increased 
time to first (or only) episode of clinical malaria among blood 
film-positive individuals (p = 0.014) (Figure 3B).
(NANP)5 responses did not correlate with the incidence of 
febrile malaria among blood film-negative individuals (p = 0.1) 
(Figure 3C), but (NANP)5 seropositivity was significantly associ-
ated with the reduced risk of and increased time to clinical malaria 
among blood film-positive individuals (p = 0.025) (Figure 3D).
Multivariate Analysis
To minimize bias through potential confounders, we developed a 
multivariable polynomial Cox regression model including the three 
critical covariates (i) age, (ii) malaria exposure, and (iii) plasma 
levels of antimerozoite stage antibodies. Increasing levels of anti-
Pfspz antibodies were independently associated with a significantly 
increased risk of experiencing clinical malaria during follow-up 
among blood film-negative individuals (p = 0.006) (Figure 4A). 
The model showed a similar trend among anti-(NANP)5 respond-
ers, with a significantly increased hazard of clinical malaria among 
blood film-negative individuals (p = 0.007) (Figure 4C). Among 
blood film-positive individuals, increasing levels of anti-Pfspz 
antibodies were associated with a decreased risk of clinical malaria 
during follow-up, although this association was not significant after 
the Bonferroni correction was applied (p =  0.035) (Figure  4B). 
Anti-(NANP)5 antibody levels were not associated with risk of 
clinical malaria during follow-up among blood film-positive 
individuals (p = 0.99) (Figure 4D).
Interaction Analysis
The relationship between antisporozoite antibodies, micro-
scopically detectable Pf parasitemia, and the incidence of clinical 
malaria was further analyzed through a Cox regression interaction 
model assessing (i) the effect of antisporozoite antibodies among 
FigUre 4 | Multivariable analysis of associations of antisporozoite antibodies against clinical malaria. Multivariable fractional polynomial Cox regression 
models estimating the independent effect of different levels of anti-Pfspz (a,B) or anti-(NANP)5 (c,D) antibodies on the incidence of clinical malaria during follow-up, 
stratified by blood film positivity and adjusted for potential confounding variables, including age, malaria exposure, and plasma levels of antibodies against blood 
stage antigens (MSP1-3, AMA1, EBA175, and Pf schizont extract); malaria exposure was measured by the proportion of infected individuals within a 1-km radius  
of an index case, calculated using weekly slide data for acute episodes, and using the cross-sectional slide data (38). (a) Among blood film-negative individuals, 
increasing anti-Pfspz levels were associated with a significantly increased rate of clinical malaria during follow-up [hazard ratio (HR) = 1.82; 95% CI = 1.19–2.81; 
p = 0.006]. (B) Among blood film-positive individuals, increasing anti-Pfspz levels were associated with a reduced rate of clinical malaria during follow-up, although 
these results were not statistically significant after applying the Bonferroni correction (HR = 0.65; 95% CI = 0.43–0.97; p = 0.035). (c) Increasing anti-(NANP)5 levels 
were associated with a significantly increased rate of clinical malaria during follow-up among blood film negatives (HR = 1.21; 95% CI = 1.05–1.40; p = 0.007).  
To reduce the skewness while maintaining the direction of association, anti-(NANP)5 optical density (OD) values were transformed to negative inverse values. (D) No 
association between increasing anti-(NANP)5 levels and a reduced rate of clinical malaria during follow-up was observed among blood film-positive individuals 
(HR = 0.99; 95% CI = 0.88–1.13; p = 0.992).
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blood film-negative individuals, (ii) the effect of microscopically 
detectable Pf parasitemia among sporozoite non-responders, and 
(iii) the effect of interactions between antisporozoite antibody 
levels and microscopically detectable Pf parasitemia on the time 
to first or only clinical malaria episode during follow-up, inde-
pendent of age and malaria exposure.
Among blood film-negative individuals, the model indicated 
an increased hazard of clinical malaria in high Pfspz responders, 
although this association was not significant after the Bonferroni 
correction (p =  0.014) (Table  1). Microscopically detectable Pf 
parasitemia significantly increased the hazard of clinical malaria 
among individuals who did not react to Pfspz (p < 0.001). Increasing 
titers of anti-Pfspz antibodies among blood film-positive indi-
viduals conferred a strong protection against clinical malaria, 
independent of age and malaria exposure (p = 0.002) (Table 1). 
Hence, the model indicated a strong interaction between the effect 
of anti-Pfspz antibody levels and Pf parasitemia on the risk of 
clin ical malaria. The effect of anti-Pfspz antibody levels was pro-
tective in blood film-positive individuals and predicted increased 
risk of first or only clinical episode in blood film-negative indi-
viduals. There was a significant difference between the model with 
and without the interaction term (likelihood ratio test: χ2 = 26.05; 
p = 0.0005). A similar model identified an association between 
increasing anti-(NANP)5 antibody levels and microscopically 
detectable Pf parasitemia on the risk of clinical malaria (p = 0.001) 
(Table 2). Again, there was a significant difference between the 
model with and without interaction term (likelihood ratio test: 
χ2 = 24.38; p < 0.0001).
TaBle 2 | effect of interactions between anti-(nanP)5 antibody levels and 
microscopically detectable Pf parasitemia on the risk of clinical malaria.
hazard ratio (95% ci) p Value
(nanP)5 antibody levels among blood film-negative 
individuals
(NANP)5 1.18 (1.05–1.31) 0.004*
Microscopically detectable Pf parasitemia per OD 
increase in anti-(nanP)5-antibody level
bf (−) 1
bf (+) 0.14 (0.03–0.67) 0.014
interaction between anti-(nanP)5 antibody levels and 
microscopically detectable Pf parasitemia
bf (+)a (NANP)5 0.77 (0.66–0.89) 0.001*
Age (years) 0.83 (0.74–0.95) 0.004*
Exposure indexb 3.57 (0.68–18.8) 0.132
Hazard ratios were computed with a logistic Cox regression model with and without 
one-, two-, or three-way interactions between anti-(NANP)5 antibodies, microscopically 
detectable blood stage Pf infection at the time of serum collection prior to the start of 
the malaria transmission season, and malaria exposure. The model assesses (i) the 
effect of anti-(NANP)5 antibody levels among blood film-negative individuals, (ii) the 
effect of microscopically detectable Pf parasitemia per OD increase in anti-(NANP)5 
antibody level, and (iii) the effect of interactions between anti-(NANP)5 antibody levels 
and microscopically detectable Pf parasitemia on the time to first malaria episode 
during follow-up, independent of age and malaria exposure index.
(NANP)5, immunodominant icosapeptide repeats of Pf circumsporozoite protein; OD, 
optical density; bf (−), blood film negatives at the time of serum collection; bf (+), blood 
film positives at the time of serum collection; Pf, Plasmodium falciparum.
*Significant at α = 0.05 after Bonferroni correction (critical value α = 0.004).
aInteraction terms.
bExposure index: proportion of infected individuals within 1 km of the index case, 
calculated using weekly slide data for acute episodes only, and using the cross-
sectional slide data.
TaBle 1 | effect of interactions between anti-Pfspz antibody levels and 
microscopically detectable Pf parasitemia on the risk of clinical malaria.
hazard ratio (95% ci) p Value
Pfspz antibody end titer among blood film-negative individuals
0 1
50–100 1.54 (0.63–3.76) 0.339
300–2,700 1.39 (0.51–3.77) 0.520
8,100–24,300 4.27 (1.34–13.58) 0.014
Microscopically detectable Pf parasitemia in Pfspz 
non-responders
bf (−) 1
bf (+) 5.12 (2.34–11.19) <0.001*
interaction between anti-Pfspz antibody levels and 
microscopically detectable Pf parasitemia
bf (+)a Pfspz (0) 1
bf (+)a Pfspz (50–100) 0.43 (0.14–1.34) 0.146
bf (+)a Pfspz (300–2,700) 0.24 (0.06–0.90) 0.035
bf (+)a Pfspz (8,100–24,300) 0.07 (0.01–0.37) 0.002*
Age (years) 0.85 (0.76–0.95) 0.005
Exposure indexb 4.42 (0.89–21.81) 0.068
Hazard ratios were computed with a logistic Cox regression model with and without 
one-, two-, or three-way interactions between Pfspz antibodies, microscopically 
detectable blood stage Pf infection at the time of serum collection prior to the start  
of the malaria transmission season, and malaria exposure. The model assesses  
(i) the effect of Pfspz antibody levels among blood film-negative individuals, (ii) the  
effect of microscopically detectable Pf parasitemia among Pfspz non-responders, 
and (iii) the effect of interactions between Pfspz antibody levels and microscopically 
detectable Pf parasitemia on the time to first malaria episode during follow-up, 
independent of age and malaria exposure index.
Pfspz, whole Pf sporozoites; Pf, Plasmodium falciparum; bf (−), blood film negatives at 
the time of serum collection; bf (+), blood film positives at the time of serum collection.
*Significant at α = 0.05 after Bonferroni correction (critical value α = 0.004).
aInteraction terms.
bExposure index: proportion of infected individuals within 1 km of the index case, 
calculated using weekly slide data for acute episodes only, and using the cross-
sectional slide data.
8
Offeddu et al. Antisporozoite Antibodies and Malaria
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 488
DiscUssiOn
In this study, we analyzed the association of naturally acquired 
antibody responses against whole Pfspz and the PfCSP CRR 
(NANP)5 with microscopically detectable Pf parasitemia and 
clinical malaria in the longitudinally monitored Chonyi cohort. 
The data indicate that robust antisporozoite immune responses 
can be naturally acquired early in life and reveal a potentially 
protective interaction between the effect of anti-Pfspz antibod-
ies and microscopically detectable Pf parasitemia on the risk of 
uncomplicated malaria.
naturally acquired humoral immunity 
against Pf sporozoites
In good agreement with previous studies (15, 39), prevalence 
and intensity of antibody responses to Pfspz and (NANP)5 were 
correlated within the Chonyi cohort. However, even among high 
Pfspz responders, some sera remained (NANP)5 negative. Slow 
acquisition of anti-(NANP)5 antibodies has already been reported 
(17). Previous studies demonstrated that endemic sera retain 
IFA signals despite depletion of anti-(NANP)n antibodies by the 
cognate peptide (39). Thus, the sera used in this study may have 
reacted to CSP antigens other than (NANP)5 or non-CSP epitopes 
present internally or on the sporozoite surface (40), suggesting 
that exclusive quantification of anti-(NANP)n titers may largely 
underestimate the prevalence and breadth of naturally acquired 
preerythrocytic humoral immune responses. This discrepancy 
may be, at least partly, explained by different sensitivities of the 
assays used. In particular, the use of air-dried, acetone fixed 
sporozoites may inactivate some epitopes on the sporozoite  sur-
face and instead expose others that are usually inaccessible to 
protective antibodies. However, since our serology data show 
that fixed sporozoites are well recognized in IFA, we anticipate 
that live sporozoites tested in follow-up studies will likely display 
comparable activity.
In this study, we confirmed an age-dependent pattern of anti-
Pfspz antibody acquisition (9–11), although we also identified 
several high responders among children, whose sera reacted to 
Pfspz at dilutions of up to 1:24,000. This is remarkable, consider-
ing that virtually all sera from adult volunteers immunized five 
times intravenously with ~135,000 metabolically active, irradia-
tion-attenuated Pf sporozoites recognized Pfspz at ≤1:7,000 in a 
similar IFA assay (41). This would indicate that naturally acquired 
immune recognition of Pfspz fundamentally differs from syringe-
injected, purified, and cryopreserved parasites.
Especially among younger age groups, the prevalence of 
antisporozoite responders was consistently higher among blood 
film-positive subjects. Whether the increased reactivity against 
sporozoites in this group could be attributable to recent or recur-
rent exposure to Pf could not be inferred based on the available 
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data. Since the presence of asymptomatic Pf infection was deter-
mined by microscopy, we cannot exclude that a significant 
proportion of blood film-negative individuals may have carried 
blood stage parasites below the microscopy detection level. In 
future studies, more sensitive methodologies, such as quantitative 
polymerase chain reaction or loop-mediated isothermal ampli-
fication, may provide a more accurate estimate of the prevalence 
of asymptomatic Pf infection among study participants.
Despite the overall lower reactivity, an age distribution of the 
prevalence of anti-(NANP)5 antibodies was detectable in this 
cohort, confirming previous findings (14, 15, 42). Microscopically 
detectable Pf parasitemia did not seem to affect acquisition of 
the anti-(NANP)5 antibody repertoire, corroborating previous 
observations that anti-(NANP)5 antibodies do not necessarily 
correlate with exposure (43, 44). On the other hand, several stud-
ies showed that anti-(NANP)n antibody res ponses fluctuate with 
seasonal or geographical transmission variation (13, 16), and out-
break investigations showed that a single sporozoite inoculation 
is able to induce humoral immunity against (NANP)n (15, 18). 
These conflicting reports may reflect epidemiological differences 
between the geographically distinct study areas.
Together, these observations support the notion of naturally 
induced acquisition of antibodies against the whole sporozoite 
and, to a lesser extent, the dominant repeat region of its main 
surface antigen. Whether the prevalence and intensity of anti-
Pfspz responses may represent a valuable marker for recent and/
or repeated exposure remains to be elucidated in further longitu-
dinal cohort studies, which should include entomological data to 
estimate the temporospatial dynamics of sporozoite transmission. 
Additional immune markers are needed to ultimately disentangle 
recent and past Plasmodium exposures.
Potentially Protective associations  
of antisporozoite antibodies with  
clinical Malaria
Previous investigations in the Chonyi cohort have shown that the 
correlation of naturally acquired antibodies to blood stage anti-
gens with the risk of disease varies depending on the presence of 
microscopically detectable Pf infection (31, 34, 45, 46). Therefore, 
the relationship of antisporozoite antibodies with malaria inci-
dence was analyzed separately in individuals who were blood film 
positive or blood film negative at sampling.
Our analysis revealed dual features of antisporozoite anti-
bodies. Among individuals who were parasite free or carrying 
Pf parasites below the level of detection by microscopy at the 
start of the malaria transmission season, high anti-Pfspz and 
anti-(NANP)5 antibody titers were significantly correlated with 
increased hazard of clinical malaria during follow-up. Acute anti-
body responses against the sporozoite are most likely elicited upon 
Pf inoculation. Blood film-negative individuals displaying higher 
antisporozoite antibody titers may have been recently exposed to 
a strong inoculation dose and, as a consequence, may be at higher 
risk of clinical malaria. Since our study only assessed humoral 
immune responses against the NF54 Pf strain, we cannot formally 
exclude that these individuals may have been infected by novel 
Pf strains to which they were immunologically unresponsive.
In marked contrast, higher levels of anti-Pfspz antibodies 
predicted a lower risk of and delayed progression to clinical 
malaria among those individuals who were blood film positive 
at the start of the malaria transmission season. Notably, we 
detected a strong and potentially protective interaction between 
the effect of both anti-Pfspz and anti-(NANP)5 antibody levels 
and microscopically detectable Pf parasitemia at the start of the 
transmission season on the risk of clinical malaria, which was 
independent of age and Pf exposure. The interaction analysis 
showed that the potentially protective effect of antisporozoite 
antibodies was greater among individuals with detectable base-
line Pf parasitemia than those who were blood film negative at 
the beginning of the malaria transmission season. Because of 
this interaction, blood film-negative and -positive individuals 
displaying high antibody titers against sporozoites may experi-
ence different risks of clinical malaria. In contrast, the difference 
in risk of disease may be comparatively similar among blood 
film-negative or -positive individuals who display low antisporo-
zoite titers. At higher antisporozoite antibody levels, blood 
film-positive individuals had significantly lower risk of malaria 
compared with blood film-negative individuals. This correlation 
was previously unrecognized and provides a rationale for future 
studies on the role(s) of preerythrocytic immunity in partial 
protection against malaria. Although highly speculative, one 
possibility is that members of the Chonyi cohort may have been 
infected by a diverse range of Pf strains, which in turn could 
have different immunological and pathogenic properties, thus 
influencing both individual immune responses and the patterns 
of clinical malaria incidence during the follow-up period. In such 
a scenario, selection through protective effects of antisporozoite 
antibodies could favor alternative strains.
One major limitation of this analysis is that data on partici-
pants’ Pf carrier status were only available from a cross-sectional 
measurement at the start of the malaria transmission season. It 
is plausible that the status of single individuals may have changed 
during the follow-up. Such changes may have affected the pat-
terns of malaria incidence in the cohort over time, but this could 
not be taken into account in this analysis.
Although naturally induced antisporozoite immunity does not 
translate into sterile protection, partial preerythrocytic immu nity 
might play a significant role in protection from clinical symptoms 
(28, 29). However, frequent inoculations over a longer time period 
might be required to induce short-lived, potentially protective 
anti-Pfspz antibodies. While such requirements might not have 
been met in the blood film-negative subset, the identification of 
children with high Pfspz antibody titers among the blood film-
positive individuals indicates that high and potentially protective 
threshold levels may be acquired early in life. These hypotheses 
are based on the findings from this data set, but do not take into 
account the variability of the data. It is possible that other sero-
logic data sets based on different cohorts or transmission settings 
may deliver contrasting results.
We cannot formally exclude that additional factors may have 
confounded this analysis. For instance, multiclonality of asymp-
tomatic Pf infections correlates with a reduced risk of subsequent 
clinical malaria (47–49), and this association is dependent on 
the intensity of transmission (50). In children, sickle cell trait 
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is independently associated with a delayed time to first clinical 
episode (51). Since these factors were not accounted for in our 
analysis, residual confounding may have occurred.
In addition, it is possible that the anti-Pfspz antibodies detected 
by IFA may actually recognize antigens that are shared between 
sporozoites and erythrocytic stages (52). Potentially protective 
anti-Pfspz antibodies detected in this study may be (i) antibodies 
that have been generated by blood stage infection but are also 
effective against sporozoites or (ii) antibodies that are effective 
against blood stages, in which case the IFA assay may have served 
as a proxy of protective blood stage responses.
Although there is currently scarce evidence that reducing the 
sporozoite load may reduce clinical malaria, possible scenarios 
for the contribution of antisporozoite antibodies to protection 
from clinical malaria include (i) reduction of sporozoite numbers 
by opsonization and subsequent phagocytosis through innate 
immune cells and (ii) blocking of essential parasite ligands for 
liver invasion receptors, as suggested by reduced sporozoite inva-
sion of human liver cell cultures in vitro following the addition of 
endemic sera (53). Both effects may ultimately limit the scale of 
liver infection and, consequently, delay or mitigate the emergence 
of liver merozoites that initiate blood stage infection. Although 
the NANP repeats of CSP represent an immunodominant B-cell 
epitope (37), it is tempting to speculate that only broad recognition 
of multiple sporozoite antigens may represent a good marker for 
recent exposure and elicit protection against subsequent malaria 
incidence.
cOnclUsiOn
Observations in Kenya and other endemic areas indicated that 
only a very small fraction of mosquito inoculations results in 
reappearance of malaria after drug treatment (54–56). While 
these observations might be partly attributed to potent blood 
stage immune responses or inefficient sporozoite inoculation 
by infected mosquitoes, they could also suggest that malaria- 
exposed individuals are able to develop partially protective immu-
nity against sporozoites. In this study, whole Pf sporozoites were 
employed for the first time as target antigen in a longitudinal 
study to assess the role(s) of naturally acquired antibodies in pro-
tective immunity against clinical malaria. A potentially protective 
contribution of antisporozoite antibodies was detected, suggest-
ing that preerythrocytic immunity might indeed contribute to 
naturally acquired protection and that antibodies against several 
sporozoite antigens might be superior than responses to single 
antigens. Several obstacles complicate the interpretation of natu-
rally acquired antibodies against sporozoites and their potentially 
protective roles. First, assessment of the relationship between 
disease and immune responses that never reach sterile protec-
tion is complex. In addition, endpoints in Pf malaria include 
microscopic detection of blood stage infection, while preeryth-
rocytic stages remain undetectable. Additional functional assays, 
such as sporozoite invasion inhibition and antibody-dependent, 
cell-mediated immunity, will add further confidence to whether 
high antisporozoite titers can effectively reduce the burden of 
this vector-borne parasitic disease and exert a hitherto neglected 
benefit in preventing clinical malaria episodes.
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